REVELATION BIOSCIENCES, INC. (REVB) Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc. NASDAQ:REVB Healthcare · Biotechnology
Mkt Cap $2.65M
EV -
SI 2.4%
Net Cash/Sh -
Prev close $3.82 +1.57%Close $3.88 -3.48%Now $3.74 VOL 13K $ Vol $50K RVOL 0.59x
Mkt Cap $2.65M
EV -
VOL 13K sh
$ Vol $50K
RVOL 0.59×
SI 2.4%
Net Cash/Sh -
Press Release
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences announced an accelerated development plan for Gemini, replacing its original AKI program with a streamlined Phase 2a study in stage 2/3 acute kidney injury initiating in early 2027 with topline data in late 2027. The redesigned study is expected to cost approximately $7 million versus roughly $60 million under the prior plan — nearly 90% lower — and will be led by investigators at Emory Healthcare and the University of Alabama at Birmingham.
• 1d ago AI analysis › Press Release
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Revelation Biosciences reported a Q3 2026 net loss of $3.3 million ($5.92 per share) versus $1.9 million a year ago, with operating expenses rising to $3.4 million from $1.9 million as the Gemini program scales toward its Phase 2/3 TITAN study in acute kidney injury. The company ended the quarter with $9.1 million in cash, down from $10.7 million at year-end, and says current cash funds operations only into the second quarter of 2027.
• 12d ago AI analysis › Press Release ● Major
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Revelation Biosciences will implement a 1-for-7 reverse stock split effective at the open on October 20, 2026, with shares continuing to trade under the REVB symbol. The stated purpose is to lift the per-share price enough to regain compliance with Nasdaq Capital Market's minimum bid price continued-listing requirement. Warrants, options, RSUs and equity plan share counts will be proportionately adjusted; fractional shares will be rounded up.
• 1mo ago AI analysis › Press Release
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 adaptive-design TITAN study. The trial will evaluate the company's proprietary formulation, Gemini, as a treatment for patients with acute kidney injury.
• 2mo ago AI analysis › Press Release
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Revelation Biosciences reported $11.5 million in cash and equivalents as of June 30, 2026, which management believes is sufficient to fund operations into the first quarter of 2027. The company recorded a net loss of $3.3 million for the second quarter, with operating expenses rising to $3.66 million compared to the prior year.
• 3mo ago AI analysis › Press Release
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Revelation Biosciences announced results from an independent market assessment identifying a $94 billion total addressable market for Gemini in Stage 2 and Stage 3 acute kidney injury. The assessment highlighted significant unmet medical need and high costs associated with AKI, with P&T committees indicating strong interest in formulary adoption.
• 3mo ago AI analysis › Press Release
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences granted 108,000 restricted stock units to three newly hired non-executive employees as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The awards are subject to a two-year vesting schedule in equal quarterly installments, with the first vesting date set for October 15, 2026.
• 3mo ago AI analysis › Press Release
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences adopted a stockholder rights plan and declared a dividend of one right for each outstanding share of common stock to protect against coercive takeover tactics. The rights become exercisable if a person or group acquires 10% or more of the common stock without board approval, allowing other holders to purchase shares at a discount to market. CEO James M.
• 4mo ago AI analysis › Press Release
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences added Dr. Peter Pickkers and Dr. Lui Forni to its Acute Kidney Injury Advisory Board. The two distinguished nephrologists and critical care physicians will guide clinical strategy for the upcoming Phase 2/3 trial of Gemini.
• 5mo ago AI analysis › Press Release
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
accessnewswire.com • 6mo ago Press Release
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences reported Q1 2026 financial results, ending the period with $14.1 million in cash, which management believes is sufficient to fund operations into the first quarter of 2027. The company announced a key regulatory milestone, reaching an agreement with the FDA on a single adaptive Phase 2/3 study for the approval of Gemini in treating acute kidney injury.
• 6mo ago AI analysis ›